TGM2 and myeloid sarcoma: Sestito et al. [39] demonstrated that this elevated TG2 in the monocytes of MS patients correlated with the progression of the clinical course of disease in MS [39,42], suggesting that TG2 is an important therapeutic target to alter the disease course in MS.